Skip to content

Crossing the Divide: Piloting Integrated Care to Reduce Amputations Among Rural Patients With Diabetic Foot Ulcers

Crossing the Divide: Piloting an Integrated Care Model to Bridge Rural-urban Healthcare Systems and Reduce Major Amputations Among Rural Patients With Diabetic Foot Ulcers

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05203471
Enrollment
131
Registered
2022-01-24
Start date
2023-02-16
Completion date
2025-06-25
Last updated
2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Amputation, Diabetic Foot, Diabetic Ulcer of Left Foot, Diabetic Ulcer of Right Foot

Keywords

Multidisciplinary care, Integrated care, Rural disparities, Recruitment, Retention

Brief summary

This project directly addresses the escalating national rate of major (above-ankle) amputations due to diabetic foot ulcers; it focuses on rural patients, who face 37% higher odds of major amputation compared to their urban counterparts. The project pilots the first integrated care model adapted to rural settings, an approach that has reduced major amputations in urban settings by approximately 40%. Pilot data will be used to improve recruitment and retention strategies and provide preliminary evidence of efficacy needed to conduct a robust, statewide efficacy trial.

Interventions

The investigators are piloting an integrated care model for rural patients with diabetic foot ulcers. The model uses two tools to promote collaboration between providers: a care algorithm and a referral checklist. The care algorithm will be used by rural primary care providers to guide integrated care addressing glycemic control, vascular disease, wound care, and infection. The referral checklist will be used by rural schedulers who place referrals to urban specialists. It prompts schedulers to fax appropriate supporting documents (e.g. notes, labs, vascular testing results) with the referral request.

Sponsors

University of Wisconsin, Madison
Lead SponsorOTHER
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
CollaboratorNIH

Study design

Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE

Intervention model description

This is an adaptive study design where recruitment and retention protocols are modified to improve involvement of rural study participants over three waves. Actively enrolled participants receive/ provide care for diabetic foot ulcers using a care algorithm and referral checklist. Results are compared to historical controls.

Eligibility

Sex/Gender
ALL
Age
18 Years to 89 Years
Healthy volunteers
No

Inclusion criteria

* Healthcare worker inclusion criteria: * Willing to provide informed consent * Willing to comply with study procedures * Rural providers (primary care physicians at the UW Health Belleville Family Medicine Clinic, diabetes and wound care specialists at Sauk Prairie Healthcare Diabetes and Wound Care Clinic) and schedulers placing referrals. * Employed at a participating clinic * For rural providers, confirm understanding that they will retain clinical discretion to deviate from the integrated care model if they think it would best serve the patient. * Available for the duration of the study * Patient inclusion criteria: * Able and willing to provide informed consent. * Willing to comply with study procedures and be available for the duration of the study. * 18 years of age and older. * Patient with either type 1 or type 2 diabetes at a participating rural clinic. * Develops diabetic foot ulcer during enrollment period.

Exclusion criteria

* Healthcare worker

Design outcomes

Primary

MeasureTime frameDescription
Proportion of Patients Receiving Guideline-concordant Vascular and Infectious Disease Care Processesup to 3 months(proportion of integrated care patients receiving guideline-concordant vascular and infectious disease care within 3 months of their enrollment) minus (the proportion of historical patients receiving guideline-concordant vascular and infectious disease care within 3 months of participant enrollment)

Secondary

MeasureTime frameDescription
Proportion of Patients Undergoing Amputationup to 3 months(proportion of integrated care patients undergoing amputation within 3 months of their enrollment) minus (proportion of historical patients undergoing amputation within 3 months of their enrollment), where amputation is defined as major (above the ankle) or minor amputation (below the ankle) of the ipsilateral lower extremity to the index ulcer.

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORMeghan B Brennan, MD

University of Wisconsin, Madison

Participant flow

Recruitment details

Patient Participants were prospectively enrolled for Integrated Care from 3 rural Wisconsin clinics and on study from February 2023 to June 2025. Historical Controls were identified from retrospective chart review. Healthcare workers (rural providers and clinic schedulers) were enrolled to make them aware of the study but there was no data collected for them.

Baseline characteristics

Characteristic
Age, Continuous64.05 years
Area Deprivation Index (ADI)4.2 units on a scale
Baseline Medications
ACE inhibitor (yes)
10 Participants
Baseline Medications
Angiotensin II receptor blocker (yes)
12 Participants
Baseline Medications
Anticoagulant (yes)
61 Participants
Baseline Medications
Statin (yes)
23 Participants
Body Mass Index (BMI)35.8 kilograms per meter squared
Ethnicity (NIH/OMB)
Hispanic or Latino
0 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
115 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
12 Participants
Preexisting Conditions
Charcot arthropathy (yes)
6 Participants
Preexisting Conditions
Coronary artery disease (yes)
12 Participants
Preexisting Conditions
Hyperlipidemia (yes)
85 Participants
Preexisting Conditions
Hypertension (yes)
21 Participants
Preexisting Conditions
Peripheral neuropathy (yes)
24 Participants
Preexisting Conditions
Stroke/TIA (yes)
11 Participants
Race (NIH/OMB)
American Indian or Alaska Native
1 Participants
Race (NIH/OMB)
Asian
0 Participants
Race (NIH/OMB)
Black or African American
0 Participants
Race (NIH/OMB)
More than one race
0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
Race (NIH/OMB)
Unknown or Not Reported
12 Participants
Race (NIH/OMB)
White
10 Participants
Region of Enrollment
United States
131 participants
Sex: Female, Male
Female
45 Participants
Sex: Female, Male
Male
25 Participants
Tobacco Status
Current User
13 Participants
Tobacco Status
Former User
43 Participants
Tobacco Status
Never User
35 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
deaths
Total, all-cause mortality
3 / 811 / 270 / 0
other
Total, other adverse events
0 / 04 / 270 / 0
serious
Total, serious adverse events
0 / 02 / 270 / 0

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 28, 2026